Press Release August 30, 2021Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months 0 0 Share
Company Ticker News August 24, 2021Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration 0 0 Share
Press Release August 24, 2021Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration 0 0 Share
Company Ticker News August 24, 2021Regeneron Pharmaceuticals Shares: $727 Target From Benchmark 0 0 Share
Company Ticker News August 20, 2021UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail 0 0 Share
Press Release August 20, 2021UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection 1 0 Share
Company Ticker News August 19, 2021Regeneron: All-Time High Share Price Hasn't Yet Reached Full Potential 0 0 Share
Company Ticker News August 17, 20213 Growth Stocks Cathie Wood Is Selling That Are Still Worth Buying 0 0 Share
Company Ticker News August 14, 2021Regeneron's Antibody Cocktail Authorized for Preventing COVID: Why It's Not a Big Deal for the Stock 0 0 Share
